In what has been a down year for mergers and acquisitions deals, Amgen made headlines late last year by announcing it will acquire Horizon for
There has been an encouraging trend in the life science industry, a growing emphasis on rare diseases. Where as little as 20 years ago, there
As the recent rise of pre-clinical initial public offerings (IPOs) indicates, investors in the life sciences no longer need to see an actual treatment to
So you read our previous post or checked out our podcast on biomarkers? Great! If not no problem, you can catch up, please click here
So you are worried about your pipeline? That’s totally valid. 90% of clinical drug candidates fail in clinical trials. Compounding the problem, drug development is
Efficiency is the name of the game these days in the life sciences. With drug development being an arduous and costly endeavor, companies are looking